期刊
IMMUNOLOGIC RESEARCH
卷 59, 期 1-3, 页码 188-202出版社
HUMANA PRESS INC
DOI: 10.1007/s12026-014-8528-x
关键词
IL-6 signaling in neoplastic plasma cells; Myeloma stem cells and minimal residual disease; Small-drug- and monoclonal antibody-based inhibitors; Genetically engineered mouse models of human myeloma
类别
资金
- NIH [5T32 AI007485]
- NCI [R01CA152105, P30CA086862, P50CA097274, R01CA151354]
- Leukemia and Lymphoma Society
- Department of Internal Medicine, Carver School of Medicine, University of Iowa
- Multiple Myeloma Research Foundation
Studies on the biologic and molecular genetic underpinnings of multiple myeloma (MM) have identified the pleiotropic, pro-inflammatory cytokine, interleukin-6 (IL-6), as a factor crucial to the growth, proliferation and survival of myeloma cells. IL-6 is also a potent stimulator of osteoclastogenesis and a sculptor of the tumor microenvironment in the bone marrow of patients with myeloma. This knowledge has engendered considerable interest in targeting IL-6 for therapeutic purposes, using a variety of antibody- and small-molecule-based therapies. However, despite the early recognition of the importance of IL-6 for myeloma and the steady progress in our knowledge of IL-6 in normal and malignant development of plasma cells, additional efforts will be required to translate the promise of IL-6 as a target for new myeloma therapies into significant clinical benefits for patients with myeloma. This review summarizes published research on the role of IL-6 in myeloma development and describes ongoing efforts by the University of Iowa Myeloma Multidisciplinary Oncology Group to develop new approaches to the design and testing of IL-6-targeted therapies and preventions of MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据